Relationship between pharmacodynamic indices and killing patterns in vitro

Future Microbiology

Volumn 6, Issue 6, 2011, Pages 613-616

  Mouton, Johan W ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Emax model; pharmacodynamics; time kill curve

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG EXPOSURE; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 79959792864     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.48     Document Type: Article

References (16)

1. Tam VH, Nikolaou M: A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Computat. Biol. 7(1), E1001043 (2011
2. Leggett JE, Fantin B, Ebert S et al.: Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159(2), 281-292 (1989 (Pubitemid 19049368)
3. Craig WA: Pharmacokinetics of antibiotics with special emphasis on cephalosporins. Clin. Microbiol. Infect. 6(Suppl. 3), 46-49. (2000
4. Ambrose PG, Bhavnani SM, Rubino CM et al.: Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44(1), 79-86 (2007 (Pubitemid 44968990)
5. Vogelman B, Craig WA: Kinetics of antimicrobial activity. J. Pediatr. 108(5 Pt 2), 835-840 (1986 (Pubitemid 16063283)
6. Mouton JW, Vinks AA: Pharmacokinetic/ pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin. Pharmacokinet. 44(2), 201-210 (2005 (Pubitemid 40188941)
7. Tam VH, Schilling AN, Nikolaou M: Modelling time-kill studies to discern the pharmacodynamics of meropenem. J. Antimicrob. Chemother. 55(5), 699-706 (2005 (Pubitemid 40691849)
8. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55(5), 601-607 (2005 (Pubitemid 40691835)
9. Mouton JW, Punt N, Vinks AA: Concentration-effect relationship of ceftazidime explains why the time above the mic is 40 percent for a static effect in vivo. Antimicrob. Agents Chemother. 51(9), 3449-3451 (2007 (Pubitemid 350067577)
10. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37(5), 1073-1081 (1993 (Pubitemid 23141323)
11. Preston SL, Drusano GL, Berman Al et al.: Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J. Am. Med. Assoc. 279(2), 125-129 (1998 (Pubitemid 28068302)
12. Scaglione F, Mouton JW, Mattina R, Fraschini F: Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob. Agents Chemother. 47(9), 2749-2755 (2003 (Pubitemid 37040243)
13. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM: Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 52(2), 123-127 (2005 (Pubitemid 40826938)
14. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155(1), 93-99 (1987 (Pubitemid 17225088)
15. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A: Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45(6), 753-760 (2007 (Pubitemid 47378891)
16. Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EA: Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50(8), 2626-2631 (2006 (Pubitemid 44198680)